Core Viewpoint - Huasheng Technology (000790.SZ) announced a complex project collaboration involving the transfer of the "smokeless moxibustion stick" drug listing license and related technology to Sichuan Binjiang Pharmaceutical for 18 million yuan, while also investing 4.5556 million yuan to acquire a 10% stake in Shanghai Aixingcheng Technology [1][2] Group 1: Transaction Details - The transfer of the "smokeless moxibustion stick" license includes granting Sichuan Binjiang Pharmaceutical national distribution rights during the transfer period, with Huasheng continuing as the exclusive manufacturer post-transfer [1] - The transaction is subject to approval by the shareholders' meeting [1] Group 2: Financial Overview of Parties Involved - Sichuan Binjiang Pharmaceutical has total assets of 2.85 million yuan and a net asset deficit of 530,000 yuan as of September 2025, with a revenue of 170,000 yuan and a net loss of 710,000 yuan for the first three quarters [1] - Shanghai Aixingcheng Technology, established in October 2025, has total assets of 41 million yuan but has recorded a net loss of 2.5 million yuan without generating revenue as of December 3 [1] Group 3: Performance Commitments - The parties involved have committed to achieving non-recurring net profits of at least 30 million yuan, 40 million yuan, and 55 million yuan for the years 2026 to 2028, respectively [2] Group 4: Financial Performance of Huasheng Technology - For the first three quarters of 2025, Huasheng Technology reported a revenue of 457 million yuan, a year-on-year decline of 31.02%, and a net loss of 97.7853 million yuan, representing a year-on-year decline of 1804.21% [2]